OBD

Oxford BioDynamics

Oxford BioDynamics Plc present strong data at ASH Summit

Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, commented: “There have been many exciting breakthroughs in the immunotherapy of cancerous and non-cancerous hematologic diseases, including immune checkpoint inhibitors. However,